Trump's conflicting policies on PBMs confuse the industry; Pfizer strikes deal to co-promote Cologuard; Tech company develops microchip for dementia patients.
FDA extends EpiPen expiration dates; GE Ventures senior managing director departs; Facebook launches MRI research project.
Studio Rx will offer services in experiential media like virtual and augmented reality, 360-degree video, and installations.
FDA gives Keytruda new real-time approval; AstraZeneca headquarters construction boondoggle; Lack of sleep costs U.S. economy hundreds of billions per year.
The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.
Azar says HHS can eliminate rebates; States pass measures to stop drug price increases; 'Poor oversight' blamed for California sitting on cash to treat mentally ill.
The renamed Evoke will replace the individual agency network with six areas of focus.
Purdue Pharma taps financial restructuring firm; White House wants opioid-production cut; NYU to make med school free.
For Gideon, honoring those who helped build the medical ad industry became a labor of love.
Teva's generic EpiPen injector received a thumbs up from the FDA on Thursday.
The study estimated the FDA's anti-smoking campaign, The Real Cost, saved $31 billion in smoking-related costs to society.
CDC estimates 72,000 died of drug overdoses in 2017; Genentech to lay off 200-plus employees; Pfizer invests up to $425 million in BioNTech.
Alphabet invests more in Oscar; ViiV's HIV injection proves effective; Gilead's chief medical officer departs in latest executive exit.
Moosmayer is set to join the pharma company in December.
Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.
Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.
WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."
Mohan was previously head of global drug-development communications.
Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.
The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.
FDA approves record number of generics in July; Trump drug-pricing policies may be hurting generic makers; Justice Department joins opioid lawsuit.
The point-of-care healthcare marketing company also conducted an initial study with Nielsen on its audience.
Rite Aid, Albertsons call off merger; AMA disapproves of CVS-Aetna deal; FDA signs off on first generic drug for CGT designation.
The partnership will give Kyne a presence in Mexico, Argentina, and Colombia.
Trump promises move to lower drug prices; CVS, Novo Nordisk beat earnings predictions; AstraZeneca settles two suits with Texas for $110 million.
Alderman is reporting to Varsha Rao, Clover's COO
Icahn asks Cigna investors to reject $54 billion Express Scripts deal; FDA changes opioid treatment evaluation; GSK names CFO.
Analysts from Jefferies predicted up to $2 billion in peak sales if Amarin's seven-year trial data is positive.
Regeneron invests $100 million in bluebird; Boehringer Ingelheim starts cystic fibrosis coalition; FDA rejects Pain Therapeutics' application to sell Remoxy.
After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.
He's filling the newly created role of EVP of integrated analytics and innovation for the agency's Chicago health practice.
Allergan sues Pfizer to cover costs of opioid lawsuits; Drug companies donate millions to areas hit by the opioid crisis; Mayo Clinic: Opioid prescriptions not decreasing.
Two late-stage orphan drugs are upping the ante with their promise to cure disease.
Alissa Kaplan, executive director, healthcare, at J. Walter Thompson, discusses work-life balance and how she manages her day.
The organization worked with Finn Partners to create the #BeTheGift campaign.
Lead Tecentriq scientist resigns; Apple hires for on-site health clinic; Novo launches DTC diabetes campaign.
Credera - like consultancies - has direct access to Fortune 500 C-suite execs.
Despite a rash of pessimism, HCPs remain engageable. Marketers must utilize open medical education hubs and CME town halls — among other tactics — to make content more engaging.
Mary Manna Anderson has joined Haymarket to lead its medical education business.
Pfizer CEO says rebates to go away; Ispos to acquire four GfK research divisions; Sanofi promises to return to growth in 2H 2018.
HCPs are still OK with hearing from pharma and medical device marketers as long as it's by email.
'Long way to go' before top pharma companies' digital presence measures up to current tech standards: study
A cross section of pharma brand websites fell short across all measured areas, including consumer experience, technology, SEO, and analytics, researchers said.
GSK consumer healthcare chief digital officer Marc Speichert talks about being a builder.
Historical big earners once again performed for Pfizer in Q2, while Ibrance broke the $1 billion barrier.
Pfizer lowers full-year forecast; Bayer to sell prescription dermatology brands to Leo; behind July's healthcare agency M&A boom.
At least six in 10 marketing chiefs globally are expecting growth in their budgets in the coming year, with 73% of UK chief marketing officers predicting a boost.
Study: Few patients use price-comparison tools to shop for lower-limb MRIs; Ascletis raises $400 million in Hong Kong IPO; California bucks trend on maternal death rates.
The agency brought on Lisa Wolfington to lead the group as director of health system marketing.
AstraZeneca promises to not raise drug prices this year; EHR adoption could lower hospital death rates: study; Roche's new drugs drive earnings.
The channel will feature content about the full range of the cancer journey.
Astellas shook up its corporate affairs department after Winton's departure.
Facebook sought to blame GDPR as it revealed its daily active users in Europe declined for the first time in nine years and it disappointed investors with lower-than-expected growth.
Alzheimer's drug slows cognitive decline; Gilead CEO to leave; Amgen migraine drug face difficulties with insurers.
Full-page Purdue print ad amended; GSK partners with 23andMe; AbbVie's endometriosis drug to cost more than $10,000 per year.
Huntsworth has stopped working with around 5% of clients in its Communications arm - which includes Grayling, Red and Citigate - as it exits "unprofitable" accounts, CEO Paul Taaffe has told PRWeek.
The Truth Initiative surveyed 9,000 young people to determine whether its campaign was really working.
Commercial chief to exit Bristol-Myers Squibb; Study: Wal-Mart $4 prescription plan a more affordable option for some Medicare patients; Trump administration pushes back on antibiotic use on farm animals.
Huntsworth has reported a 5.4% fall in like-for-like revenue at its PR agencies in the first half of 2018, led largely by declines at Grayling after the "elimination of unprofitable client contracts."
The holding company's net revenue jumped 5.6% in the second quarter.
Data on medical education spending show a continued increase in investment from the pharma and medical device industries.
Bayer to stop selling Essure; FDA approves Agios' leukemia treatment; Investor lawsuit targets Theranos.
This year's Cannes Lions festival made 9% less revenue than in 2017 owing to falls in both delegate numbers and awards entries resulting from Publicis Groupe sitting out the event and the organizers truncating the schedule.
Reid Connolly talks the benefits of buying San Francisco-based firm Giant.
More drugmakers vow to halt price increases; FDA considers allowing imported drugs in some cases; Trump administration examines rebates.
The holding company has launched a review of its Publicis Health Solutions business after a volatile Q2.
Healthcare decline weighs on Publicis Q2 earnings; Gottlieb releases biosimilar plan; Roche's lung cancer treatment shows positive results.
Being named among the MM&M Best Places to Work can help you stand out in the race for talent. Here's how the contest works.
Celgene's drug will now have time to establish itself in the market without generic competition.
The company posted a sales increase of 10.6% in the second quarter.
Novartis voluntarily halts price increases; Shkreli's former company considers name change; FDA issues guidance to modernize electronic health data in trials.
Payer Sciences is a health marketing agency that uses data and analytics to gather insights about payer behavior.
Prophet surveyed 240 healthcare organizations to find out where the industry is actually at on its shift to consumer centricity.
The holding company's overall revenue was up 1.8% in the period to $3.9 billion.
J&J beats expectations on Q2 earnings; AbbVie, Mylan sign U.S. license deal for Humira; Roche's new flu drug meets endpoints.
Huntsworth has continued its expansion by taking a majority stake in U.S. independent healthcare marketing agency Giant Creative Strategy for an initial sum of $72.2m.
Vital Health is driven by Ketchum's new analytics tool, Vital Diagnostics.
The Publicis-owned agency has laid off around 100 people in the U.S. alone this week
Dolin is overseeing offices in New York, New Jersey, Connecticut, and Canada.
MM&M Awards shortlist revealed; FDA approves first smallpox treatment; Another way Amazon could drive down healthcare costs.
Find out who made award-winning work this year.
Alexa could make it easier for doctors to squeeze CME programs into their busy schedules.
Doner will lead a branding effort for the health system that will roll out in 2019.
Wednesday's reorg was designed to position the company for growth in the face of the imminent patent cliff for megablockbuster Lyrica.
The agency said Jeremy Perrott violated the agency's code of conduct.
New report reveals large amount of opioids shipped to Missouri; Humana partners with Walgreens; Wyden requests details on Trump-Pfizer agreement
If you were unfamiliar with MediaMonks and want to know more about the company that Martin Sorrell has made his first capture, read on.
Tham Khai Meng has been with Ogilvy since 1999.
He's a veteran of Deep Focus, Wunderman, and ATTIK.
The government agency released its latest guidance this week.
Some Twitter accounts could lose millions of followers when the social platform purges large numbers of "locked" accounts this week.
Pfizer announces restructuring hours after about face on price hikes; Feds to slash funding for ACA "navigators"; Study finds rural states lag in combating heart disease.
In an interview with Campaign, Sir Martin Sorrell insisted his new company, S4 Capital, is listening to clients because they are "questioning" how agencies are delivering work.
Sir Martin Sorrell's S4 Capital has agreed to buy Dutch content business MediaMonks in a deal that is strikingly different from how he structured acquisitions at WPP.
Directing its reps to call on GPs with little to no opioid experience, Purdue introduced aggressive promotional tactics into the prescription opioid marketing playbook.
Biogen's recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
CMS ends plan to make Novartis cancer treatment cheaper; Trump calls out Pfizer on Twitter for price hikes; News organizations sue to get federal opioid data.
The most comprehensive look at the pharma and healthcare agency world from MM&M.
The deals follow last year's additions of Cambridge BioMarketing and MicroMass Communications.
Positive Alzheimer's trial sends Biogen shares surging; A year after crisis, analysts come around to AstraZeneca stock; Ironwood cuts 40 jobs ahead of split.